ATS 2019 Virtual Final Program

10:45 Eosinophils as Host Defense Cells A.E. Samarasinghe, PhD, Memphis, TN 11:15 Innate Lymphoid Cells in Viral Lung Infections D.C. Newcomb, PhD, Nashville, TN 11:45 LUNCH 12:45 Lung Immunity Learns from Experience: Influence of Antecedent Infection J.P. Mizgerd, ScD, ATSF, Boston, MA 1:15 Antimicrobial Immunity and Chronic Lung Disease C. Dela Cruz, MD, PhD, ATSF, New Haven, CT 1:45 Airway Microbiome and Innate Immunity R.P. Dickson, MD, Ann Arbor, MI 2:15 Break 2:30 Neutrophil Recruitment, Activation, and Homeostasis in Pneumonia H.R. Luo, PhD, Boston, MA 3:00 Visualizing Integrated Immune Responses in the Lung J. Bhattacharya, MD, PhD, New York, NY 3:30 Harvesting Innate Immune Function to Protect Patients from Pneumonia S.E. Evans, MD, Houston, TX BASIC • CLINICAL • TRANSLATIONAL POSTGRADUATE COURSE CME Credits Available: 7 PG22 ALL THINGS NTM: A ROAD MAP TO THE DIAGNOSIS AND MANAGEMENT OF NONTUBERCULOUS MYCOBACTERIA R Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited. Member: $350 In-Training Member: $200 Non-Member: $425 In-Training Non-Member: $300 : Registrants must bring a laptop to the course to view the course material. Assembly on Pulmonary Infections and Tuberculosis 8:00 a.m. - 4:00 p.m. KBHCCD Room D171/D173 (Level 1) Target Audience Pulmonary and critical care physicians, pulmonary fellows, infectious disease fellows, internal medicine residents, medical students, pulmonary and infectious disease nurse practitioners, physician assistants, internal medicine providers Objectives At the conclusion of this session, the participant will be able to: • learn new findings and apply the latest in epidemiologic trends and diagnostic modalities in patients with suspected NTM lung disease; • apply and learn the latest in research in the management of NTM lung infections; • reinforce guideline based therapy for newly diagnosed and refractory NTM lung disease as well as discuss tools to improve adherence to medical therapy through an interactive case-based panel discussion. The course will provide an overview and update on the latest in nontuberculous mycobacterial (NTM) lung disease. It will discuss recent epidemiologic trends, radiology, microbiology, diagnosis and management of NTM lung disease in different populations. It will discuss the latest in research (including results from the National Bronchiectasis NTM Research Registry, epidemiologic research and recent clinical trials). It will also involve an interactive case-based panel discussion discussing common and difficult real-world NTM patient scenarios. Finally, the course will include an FDA perspective on drug development and areas of needed research. Chairing: S.H. Kasperbauer, MD, Denver, CO A. Basavaraj, MD, New York, NY K.N. Olivier, MD, MPH, Bethesda, MD 8:00 Epidemiology of NTM R. Prevots, PhD, MA, Bethesda, MD 8:30 Environmental Sources of NTM R. Thomson, MBBS, PhD, Brisbane, Australia 9:00 Host Vulnerability A.E. O’Donnell, MD, Washington, DC 9:30 Break 9:40 The Management of Pulmonary MAC D.E. Griffith, MD, Tyler, TX 10:10 The Management of Pulmonary M. Abscessus Complex S.H. Kasperbauer, MD, Denver, CO 10:40 Treatment of Less Commonly Encountered NTM J. Philley, MD, Tyler, TX 11:10 Management of Drug Resistant NTM Infections K.N. Olivier, MD, MPH, Bethesda, MD 11:40 Non-Pharmacologic Therapies and Airway Clearance A. Basavaraj, MD, New York, NY 12:10 LUNCH 12:50 NTM Cases in the Community K.A. Cohen, MD, Baltimore, MD 1:20 Cystic Fibrosis Related NTM Infection A. Floto, MD, PhD, Cambridge, United Kingdom 1:50 Surgical Approach to the Management of NTM Infections J.D. Mitchell, MD, Aurora, CO 2:20 What’s New in NTM Treatment and Where Should We Focus Our Research Efforts? C.L. Daley, MD, Denver, CO 2:50 Break 3:00 Drug Development, the FDA Perspective P. Kim, MD, Silver Spring, MD 3:30 Difficult to Manage NTM Cases M. Holt, MBBS, BSc, Brisbane, Australia ATS 2019 • Dallas, TX 20 SATURDAY • MAY 18